08:00 , Mar 28, 2005 |  BC Week In Review  |  Company News

Forest Laboratories sales and marketing update

FRX launched its Combunox oxycodone and ibuprofen tablets to treat moderate to severe pain. FRX has a license to the compound from BTG plc (LSE:BGC London, U.K.). Forest Laboratories Inc. (FRX), New York, N.Y.  ...
08:00 , Oct 28, 2002 |  BC Week In Review  |  Clinical News

Oxycodone/ibuprofen regulatory update

The FDA issued an approvable letter to FRX for its oxycodone/ibuprofen combination to treat pain. However, FRX said the agency requested in the letter that additional clinical trials be conducted to further establish safety and...
07:00 , Oct 21, 2002 |  BC Extra  |  Company News

Forest's oxycodone receives approvable letter

The FDA issued an approvable letter to Forest (FRX) for its oxycodone/ibuprofen combination to treat pain. However, FRX said the agency requested that additional clinical trials to further establish safety and efficacy. FRX licensed the...
08:00 , Dec 24, 2001 |  BC Week In Review  |  Clinical News

Oxycodone/ibuprofen regulatory update

BGC said licensee FRX submitted an NDA to the FDA to market Oxycodone HCl/ibuprofen to treat moderate and severe pain. Oxycodone combined with aspirin already is marketed, BTG said. BTG plc (LSE:BGC), London, U.K.  ...
08:00 , Dec 21, 2001 |  BC Extra  |  Company News

Forest submits Oxycodone/Ibuprofen NDA

FRX submitted an NDA to the FDA for its Oxycodone/Ibuprofen to treat moderate-to-severe pain. The product was licensed from BTG (LSE:BGC)....